Livdelzi (seladelpar) is a medication approved by the FDA for treating primary biliary cholangitis (PBC) in adults. It can be used in combination with ursodeoxycholic acid (UDCA) for those who do not respond adequately to UDCA alone or as a monotherapy for those who cannot tolerate UDCA. Livdelzi works by reducing alkaline read more

Livdelzi (seladelpar) is a medication approved by the FDA for treating primary biliary cholangitis (PBC) in adults. It can be used in combination with ursodeoxycholic acid (UDCA) for those who do not respond adequately to UDCA alone or as a monotherapy for those who cannot tolerate UDCA. Livdelzi works by reducing alkaline phosphatase (ALP) levels, which are often elevated in PBC.

How to Take Livdelzi:
- Taken orally as a capsule once daily, with or without food.
- Follow the exact dosing schedule prescribed by your healthcare provider.

Common Side Effects:
- Headache
- Abdominal pain
- Nausea
- Abdominal distension (bloating)
- Dizziness

Rare but Serious Side Effects:
- Fractures
- Liver test abnormalities
- Biliary obstruction (blockage in the bile ducts)

Monitoring and precautions should be taken as advised by your healthcare provider. For more information, you can visit the Livdelzi page on myPBCteam.

 This AI-generated response comes from myPBCteam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Livdelzi (Seladelpar) for PBC | myPBCteam

Primary Biliary Cholangitis Treatments and Their Side Effects | myPBCteam